Company: SXTPW
Filing Date: 2025-07-16
Form Type: 424B4
Source: 0001213900-25-064472
Chunk: 32

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-07-16
Form: 424B4
Chunk 32
---
 Stock (the “February 2025 Placement Agent Warrants”). The February 2025 Placement
Agent Warrants have an exercise price equal to $4.469 per share and are exercisable upon issuance, or February 6, 2025, and expire twenty-four
months from the date of issuance.

The Company received net proceeds of $908,627
from the offering, after deducting estimated offering expenses paid by the Company, including the placement agent fees. The Company has
used and intends to use the net proceeds from the offering for general corporate purposes, including working capital.

January 2025 Offering

On January 28, 2025, we entered into a securities
purchase agreement (the “January 2025 Securities Purchase Agreement”) with certain institutional investors (the “January
2025 Purchasers”) pursuant to which the Company sold, in a registered direct offering an aggregate of 204,312 shares (the “January
2025 Shares”) of common stock at a purchase price of $5.105 per share in a registered direct offering priced at-the-market under
the rules of Nasdaq. The January 2025 Offering closed on January 30, 2025.

<div align='center'>13</div>

The January 2025 Shares were offered pursuant
to a “shelf” registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the SEC on
July 18, 2024 as supplemented by a prospectus supplement dated January 28, 2025, filed with the SEC on January 30, 2025, and accompanying
base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act.

In a concurrent private placement, the Company
also issued to the January 2025 Purchasers unregistered warrants (the “January 2025 Warrants”) to purchase up to an aggregate
of 408,621 shares of common stock at an exercise price of $3.855 per share, subject to certain adjustments. The January 2025 Common Warrants
are exercisable upon issuance and expire twenty-four months from the date of issuance.

The Selling Shareholder S-1 registered the January
2025 Shares and the shares underlying the January 2025 Warrants.

The issuance of the January 2025 Warrants pursuant
to the January 2025 Securities Purchase Agreement and issuance of the January 2025 Placement Agent Warrants (defined below) were made
pursuant